Browsing Tag
oral insulin
1 post
Lifeward (Nasdaq: LFWD) bets on oral insulin platform to escape medical device treadmill
Lifeward (LFWD) posts full-year 2025 revenue of $22M, down 14%, as shareholders approve the Oramed POD platform deal. Here is what it means for LFWD investors. Read more.